HIGHLIGHTS
- who: Domenica Lorusso and collaborators from the National Institutes of Health (NIH), United States The University of Sydney, Australia have published the Article: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma, in the Journal: (JOURNAL)
- what: Next, the authors focus on the common adverse events associated with lenvatinib and guide how to optimally prevent, detect, and manage them, while minimizing interruptions during lenvatinib treatment.
- how: In vivo data indicated that lenvatinib is extensively metabolized through non-P450-mediated pathways including oxidation by aldehyde oxidase glutathione conjugation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.